Indivumed GmbH has established the world’s leading cancer database, combining molecular and clinical data from targeted tumor tissue and related biological materials. By controlling for pre-analytical variability associated with resected tumor tissue, Indivumed provides the world’s only comprehensive gene and protein profile databases of cancer, supporting the development of new CDx and therapeutics. Indivumed’s standardized biospecimen collection process has enabled the recruitment of over 24,000 patients, securing in excess of 600,000 samples and more than 4.5 million clinical data points.